AM679
AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye[1].
Product Specifications
CAS Number
1206880-66-1
UNSPSC
12352005
Target
FLAP
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/AM679.html
Purity
99.72
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C)N1C2=CC=CC=C2C[C@H]1COC3=CC=C(N(CC4=CC=C(C5=NC=C(OC)C=N5)C=C4)C(CC(C)(C(O)=O)C)=C6SC(C)(C)C)C6=C3
Molecular Formula
C40H44N4O5S
Molecular Weight
692.87
References & Citations
[1]Stock, N, et al. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5- ((S) -1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy) -3-tert-butylsulfanyl-1-[4- (5-methoxy-pyrimidin-2-yl) -benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679) -A potent FLAP inhibitor. Bioorganic & Medicinal Chemistry Letters (2010), 20 (1), 213-217.|[2]Musiyenko, A, et al. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clinical and Vaccine Immunology (2009), 16 (11), 1654-1659.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15090903 1 Vial
Lentiviral human RNF10 shRNA (UAS) - Lentiviral human RNF10 shRNA (UAS, iRFP) (100)
Sign In for Pricing
View Details 